News

World Class Hospitals Join DNA Damage Response Consortium to Bring Forward New Treatments for Adults and Children with Brain Cancer Researchers from St. Jude Children’s Research Hospital, NYU, UCSF, and the University of Minnesota join National Brain Tumor Society and Yale-led Initiative   Today, the National Brain Tumor Society (NBTS), in partnership with Yale Cancer Center, announced new partners for its DNA Damage Response Consortium. Joining the initiative are world-class experts in adult and pediatric neuro-oncology […] March 28, 2023

NBTS Brain Tumor Clinical Trials Report: Q4 2021 It can be hard to keep track of new clinical trial opportunities opening across the United States, especially as we continue to navigate the public health crisis created by the coronavirus (COVID-19). There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started […] January 13, 2022

SNO-Cap 2018: Recapping The Annual Meeting and Education Day of the Society for Neuro-Oncology The Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) continues to grow. Each of the last few years, SNO has reported new records for conference registration, attendees, and the number of presentations submitted for consideration. The 23rd annual SNO meeting in New Orleans, LA from Thursday, November 15 through Sunday, November 18 […] December 17, 2018

Passionate About Patients: Q&A With New NBTS Chief Scientific Officer, Kirk Tanner A couple of weeks ago, we introduced Kirk Tanner, PhD, as the National Brain Tumor Society’s new Chief Scientific Officer. The official announcement contained a good deal of biographical information regarding Kirk’s education, work history, and experience helping to develop new medicines as a senior director, staff scientist, and oncology research leader for a major […] November 30, 2018

Beating the Odds Thanks to Research Funding: Greg’s Story After an otherwise-healthy and vibrant 24-year old newlywed was diagnosed with an aggressive brain tumor and given just two-to-three years to live, a new clinical trial – based on NBTS-funded research – provided hope and helped beat the odds. “Temozolomide is what it is: a chemotherapy,” says Greg. “This means constantly feeling drained of your […] November 13, 2017